| Compassionate Therapeutic Solutions. LLC (OTC.PK: GLGT)
Compassionate Therapeutic Solutions is your answer when it comes to full service solutions for your practice. CTS provides guidance and solutions relating to products that have been identified as a beneficial and legal answer for individuals suffering from conditions identified in the Colorado medical marijuana law.
Professional standards guided by ethical practices is imperative when it relates to you or someone you treat with debilitation conditions. Increasing professional relationships is the answer and CTS is here to provide leadership and solutions for managing this frequently abused medication. We are the professionals resource, your resource.
The total cannabis market in the U.S. is estimated at $10-15 billion range.
Providing Legitimate Options:
It is the law in Colorado and CTS has been acknowledged as a professional organization backing professional involvement. Professionally driven and regulated services is the answer.
Individuals not interested in treatment will not be accepted as a patient. Providing legitimate options through the therapeutic process is the law and CTS has solutions. Associates will be provided reports, consulting guidance and consistent certified products that permit medication monitoring trials.
Compassionate Therapeutic Solutions is a contributor and supporter for legal clarification and defining primary / caregiver relationships as defined by Colorado law. Both bills are heavily based on care giver relationships and CTS is able to provide the answers for your practice. Compassionate Therapeutic Solutions wellness practice offers compassionate, knowledgeable, and licensed professional services and products. From the beginning, your experience will be treatment driven. Our licensed professionals will consult and provide guidance for your practice.
Facts about Medical Marijuana.
Medical Marijuana
1. "By design CMCR [Center for Medicinal Cannabis Research] clinical studies focused on conditions identified by the Institute of Medicine for which cannabis might have potential therapeutic effects, based on current scientific knowledge (Institute of Medicine, 1999). To date, four CMCR-funded studies have demonstrated that cannabis has analgesic effects in pain conditions secondary to injury (e.g. spinal cord injury) or disease (e.g. HIV disease, HIV drug therapy) of the nervous system ... This suggests that cannabis may provide a treatment option for those individuals who do not respond or respond inadequately to currently available therapies. The efficacy of cannabis in treatment-refractory patients also may suggest a novel mechanism of action not fully exploited by current therapies. In addition to nerve pain, CMCR has also supported a study on muscle spasticity in Multiple Sclerosis (MS). Such spasticity can be painful and disabling, and some patients do not benefit optimally from existing treatments. The results of the CMCR study suggest that cannabis reduces MS spasticity, at least in the short term, beyond the benefit available from usual medical care."
2. Synopsis of CMCR Published Clinical Study Results
“The Effect of Cannabis on Neuropathic Pain in HIV-Related Peripheral Neuropathy”
Donald I. Abrams, M.D., University of California, San Francisco
"The primary objective of this study was to evaluate the efficacy of smoked cannabis when used as an analgesic in persons with neuropathic pain from HIV-associated distal sensory polyneuropathy (DSPN) ... In a double blind, randomized, five-day clinical trial patients received either smoked cannabis or placebo cannabis cigarettes .... The full results of this study appear in the journal Neurology (Abrams, et al., 2007– see reference list) ... The study concluded that a significantly greater proportion of patients who smoked cannabis (52%) had a greater than 30% reduction in pain intensity compared to only 24% in the placebo group."
“Placebo-Controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy”
Ronald J. Ellis, M.D., Ph.D., University of California, San Diego
"The primary objective of this study also was to evaluate the efficacy of smoked cannabis when used as an analgesic in persons with HIV-associated painful neuropathy. In a double-blind, randomized, clinical trial of the short-term adjunctive treatment of neuropathic pain in HIV-associated distal sensory polyneuropathy, participants received either smoked cannabis or placebo cannabis cigarettes ... The full results of this study were published in the journal Neuropsychopharmacology (Ellis, et al., 2008 – see reference list) ... It was concluded that smoked cannabis was generally well-tolerated and effective when added to concomitant analgesic therapy in patients with medically refractory pain due to HIV-associated neuropathy."
“A Double-Blind, Placebo-Controlled Crossover Trial of the Antinociceptive Effects of Smoked Marijuana on Subjects with Neuropathic Pain“
Barth Wilsey, M.D., University of California, Davis
"This study’s objective was to examine the efficacy of two doses of smoked cannabis on pain in persons with neuropathic pain of different origins (e.g., physical trauma to nerve bundles, spinal cord injury, multiple sclerosis, diabetes). In a double-blind, randomized clinical trial participants received either lowdose, high-dose, or placebo cannabis cigarettes ... The full results of this study have been published in the Journal of Pain (Wilsey, et al., 2008 – see reference list) ...The study concluded that both low and high cannabis doses were efficacious in reducing neuropathic pain of diverse causes."
“Analgesic Efficacy of Smoked Cannabis”
Mark Wallace, M.D., University of California, San Diego
"This study used an experimental model of neuropathic pain to determine whether pain induced by the injection into the skin of capsaicin, a compound which is the 'hot' ingredient in chili peppers, could be alleviated by smoked cannabis. Another aim of the study was to examine the effects of 'dose' of cannabis, and the time course of pain relief. In a randomized double-blinded placebo controlled trial, volunteers smoked low, medium, and high dose cannabis (2%, 4%, 8% THC by weight) or placebo cigarettes ... The full results of this study were published in the journal Anesthesiology (Wallace, et al., 2007 – see reference list) ...In summary, this study suggested that there may be a 'therapeutic window' (or optimal dose) for smoked cannabis: low doses were not effective; medium doses decreased pain; and higher doses actually increased pain. These results suggest the mechanism(s) of cannabinoid analgesia are complex, in some ways like non-opioid pain relievers (e.g., aspirin, ibuprofen) and in others like opioids (e.g., morphine)."
“Short-Term Effects of Cannabis Therapy on Spasticity in Multiple-Sclerosis”
Jody Corey-Bloom, M.D., University of California, San Diego
"This objective of this study was to determine the potential for smoked cannabis to ameliorate marked muscle spasticity (chronic painful contraction of muscles), a severe and disabling symptom of multiple sclerosis ... In a placebo-controlled, randomized clinical trial spasticity and global functioning was examined before and after treatment with smoked cannabis ... Initial results were presented at the meeting of the American College of Neuropsychopharmacology in 2007 ... This study concluded that smoked cannabis was superior to placebo in reducing spasticity and pain in patients with multiple sclerosis, and provided some benefit beyond currently prescribed treatments."
“Vaporization as a ‘Smokeless’ Cannabis Delivery System”
Donald Abrams, M.D., University of California, San Francisco
"The aim of this study was to evaluate the use of a vaporization system (the Volcano; VAPORMED® Inhalatoren; Tüttlingen, Germany) as a 'smokeless' delivery system for inhaled cannabis ... The full results of this study have been published in the journal Clinical Pharmacology & Therapeutics (Abrams, et al., 2007 – see reference list) ... In summary, vaporization of cannabis was found to be a safe mode of delivery, and participants had a preference for vaporization over smoking as a delivery system in this trial."
3. "Evidence not only supports the use of medical marijuana in certain conditions but also suggests numerous indications for cannabinoids. Additional research is needed to further clarify the therapeutic value of cannabinoids and determine optimal routes of administration. The science on medical marijuana should not be obscured or hindered by the debate surrounding the legalization of marijuana for general use."
4. "Cannabinoids have been found to have antioxidant properties, unrelated to NMDA [(N-methyl-D-aspartic acid] receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention."
5. "Cannabinoids, the active components of Cannabis sativa and their derivatives, act in the organism by mimicking endogenous substances, the endocannabinoids, that activate specific cannabinoid receptors. Cannabinoids exert palliative effects in patients with cancer and inhibit tumour growth in laboratory animals.
"The best-established palliative effect of cannabinoids in cancer patients is the inhibition of chemotherapy-induced nausea and vomiting. ....
"Other potential palliative effects of cannabinoids in cancer patients — supported by Phase III clinical trials — include appetite stimulation and pain inhibition. ....
"Cannabinoids inhibit tumour growth in laboratory animals. They do so by modulating key cell-signalling pathways, thereby inducing direct growth arrest and death of tumour cells, as well as by inhibiting tumour angiogenesis and metastasis.
"Cannabinoids are selective antitumour compounds, as they can kill tumour cells without affecting their non-transformed counterparts. It is probable that cannabinoid receptors regulate cell-survival and cell-death pathways differently in tumour and nontumour cells.
"Cannabinoids have favourable drug-safety profiles and do not produce the generalized toxic effects of conventional chemotherapies. ... "
Approved Conditions for Medical Marijuana Use:
- Arthritis
- Multiple Sclerosis
- Glaucoma
- Cancer
- Epilepsy / Seizures
- Pain Management
Medical Marijuana Support Website: http://www.mpp.org/
List of US States that have legalized Medical Marijuana
|
State
|
Year Passed
|
Possession Limit
|
Accepts other states' registry ID cards?
|
|
1. Alaska
|
1998
|
1 oz usable; 6 plants (3 mature, 3 immature)
|
Unknown *
|
|
2. California
|
1996
|
8 oz usable; 18 plants (6 mature, 12 immature)**
|
No
|
|
3. Colorado
|
2000
|
2 oz usable; 6 plants (3 mature, 3 immature)
|
No
|
|
4. Hawaii
|
2000
|
3 oz usable; 7 plants (3 mature, 4 immature)
|
No
|
|
5. Maine
|
1999
|
2.5 oz usable; 6 plants
|
Yes
|
|
6. Michigan
|
2008
|
2.5 oz usable; 12 plants
|
Yes
|
|
7. Montana
|
2004
|
1 oz usable; 6 plants
|
Yes
|
|
8. Nevada
|
2000
|
1 oz usable; 7 plants (3 mature, 4 immature)
|
No
|
|
10. New Jersey
|
2010
|
2 oz usable
|
Unknown
|
|
9. New Mexico
|
2007
|
6 oz usable; 16 plants (4 mature, 12 immature)
|
No
|
|
11. Oregon
|
1998
|
24 oz usable; 24 plants (6 mature, 18 immature)
|
No
|
|
12. Rhode Island
|
2006
|
2.5 oz usable; 12 plants
|
Yes
|
|
13. Vermont
|
2004
|
2 oz usable; 9 plants (2 mature, 7 immature)
|
No
|
|
14. Washington
|
1998
|
24 oz usable; 15 plants
|
No
|
The first question a potential medical marijuana patient must answer is do I qualify for a medical marijuana card?
Please review the list of qualifying medical conditions as laid out by the department of Public Health and Environment below.
- Severe or Chronic Pain
- Cancer
- Glaucoma
- HIV or AIDS positive OR A medical condition or treatment that produces, for this patient, one or more of the following and which, in the physician’s professional opinion, may be alleviated by the medical use of marijuana.
- Cachexia
- Severe nausea
- Seizures (including those characteristic of epilepsy)
- Muscle spasticity or spasms (related to some of the above conditions.)
- Persistent muscle spasms (including those characteristic of multiple sclerosis)
To register with the Colorado Medical Marijuana Registry interested applicants must send in a signed physician referral form and complete and sign a registry application form. If you currently don't have a physician or would like to change your physician we can assist in finding an authorized physician for you to see. At CTS we are prepared to walk and talk you through the process of getting registered with the Colorado Medical Marijuana Registry from start to finish. Please see how simple the process is in the requirements list below.
Colorado Medical Marijuana Card Registration Requirements:
- Completing an application form for a medical marijuana registry (ID) or identification card
- Sign and date the registry application form
- Have the physician sign and date the physician recommendation form
- Photocopy a legible copy of an approved photo I.D. that establishes Colorado residency.
- Send in a non refundable application fee of $90 (check or money order payable to (CDPHE)
|
